
Fortress Biotech, Inc.: updates and filings
Price
$1.89
November 18, 2026Market cap $59M
What Ploutos Investor adds for Fortress Biotech
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from 2013
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The reported profit is far larger than a business usually earns on its market value, which usually means one-off or accounting gains. We leave out the P/E and the earnings yield.
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
- A figure that did not match the numbers it is built from has been left out.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 13, 2026next Feb 12, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
August 2026
May 2026
March 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 13, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 13, 2026Results of operationsForm8-K
- Oct 29, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 1, 2026Other material eventsForm8-K
- Sep 1, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 13, 2026Results of operationsForm8-K
- Jun 23, 2026Shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 14, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 14, 2026Results of operationsForm8-K
- Apr 28, 2026Additional annual meeting materialFormDEFA14A
- Apr 28, 2026Annual meeting proxy statementFormDEF 14A
- Mar 31, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 31, 2026Results of operationsForm8-K
- Mar 30, 2026Other material eventsForm8-K
- Mar 20, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Feb 23, 2026Material agreement entered, new material financial obligation, other material eventsForm8-K
- Jan 13, 2026Other material eventsForm8-K
- Jan 6, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jan 5, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Dec 17, 2025FilingFormEFFECT
- Dec 16, 2025Correspondence with the SECFormCORRESP
- Dec 16, 2025FORM S-1FormS-1
- Dec 15, 2025Material agreement entered, new material financial obligation, unregistered sale of sharesForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 13, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 13, 2026 | 8-K | Results of operations | Document |
| Oct 29, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 1, 2026 | 8-K | Other material events | Document |
| Sep 1, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 13, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 13, 2026 | 8-K | Results of operations | Document |
| Jun 23, 2026 | 8-K | Shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 14, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 14, 2026 | 8-K | Results of operations | Document |
| Apr 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 28, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 31, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 31, 2026 | 8-K | Results of operations | Document |
| Mar 30, 2026 | 8-K | Other material events | Document |
| Mar 20, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Feb 23, 2026 | 8-K | Material agreement entered, new material financial obligation, other material events | Document |
| Jan 13, 2026 | 8-K | Other material events | Document |
| Jan 6, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jan 5, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Dec 17, 2025 | EFFECT | Filing | Document |
| Dec 16, 2025 | CORRESP | Correspondence with the SEC | Document |
| Dec 16, 2025 | S-1 | FORM S-1 | Document |
| Dec 15, 2025 | 8-K | Material agreement entered, new material financial obligation, unregistered sale of shares | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Mar 5, 2008. Of its note and share prospectuses (424B, FWP), the newest 40 of 45.
The full analysis
What do Fortress Biotech's filings show?
The filings are where every one of Fortress Biotech's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.